Payment overview · 2025
General Payments
$481.52
25 reported records · 15 companies
Healthcare provider profile · identity verified
Debra Garrison, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FLORENCE, SC · NPI 1427623008
Verified facts
What the public records show
CMS Open Payments records show Debra Garrison, NP received $481.52 in general payments during 2025 across 25 reported records.
Sage Therapeutics, LLC accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $105.58 | 21.9% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $72.31 | 15.0% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $48.67 | 10.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.02 | 7.5% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $29.07 | 6.0% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $28.12 | 5.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.70 | 5.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.37 | 5.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.34 | 4.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.20 | 3.6% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $16.59 | 3.5% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $16.50 | 3.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.22 | 3.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.92 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.91 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $481.52 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $105.58 | 4 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $51.21 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $48.67 | 2 | 2025 |
Source payment records
|
|||||
| FIBRYGA Normalized: fibryga |
Biological | Octapharma USA, Inc. | $29.07 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $28.12 | 2 | 2025 |
Source payment records
|
|||||
| Kyleena Normalized: kyleena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| Lynkuet Normalized: lynkuet |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| Mirena Normalized: mirena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 548 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 409 | 88 |
| Fluticasone Propionate | Fluticasone Propionate | 204 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 203 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 48 |
| Lisinopril | Lisinopril | 176 | 36 |
| Losartan Potassium | Losartan Potassium | 155 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 33 |
| Gabapentin | Gabapentin | 134 | 33 |
| Montelukast Sodium | Montelukast Sodium | 125 | 36 |
| Omeprazole | Omeprazole | 122 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 113 | 24 |
| Allopurinol | Allopurinol | 108 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 25 |
| Trazodone Hcl | Trazodone Hcl | 92 | 15 |
| Famotidine | Famotidine | 91 | 26 |
| Nifedipine Er | Nifedipine | 89 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 16 |
| Metformin Hcl | Metformin Hcl | 74 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 17 |
| Ezetimibe | Ezetimibe | 67 | 21 |
| Carvedilol | Carvedilol | 64 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | suppressed |
| Ibuprofen | Ibuprofen | 56 | 26 |
| Metformin Hcl Er | Metformin Hcl | 56 | 12 |
| Potassium Chloride | Potassium Chloride | 52 | 12 |
| Linzess | Linaclotide | 50 | 15 |
| Prednisone | Prednisone | 48 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Meloxicam | Meloxicam | 42 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 19 |
| Colchicine | Colchicine | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Furosemide | Furosemide | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 22 |
| Jardiance | Empagliflozin | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Baclofen | Baclofen | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $481.52 · 25 records | Sage Therapeutics, LLC | ACCRUFER, AREXVY, Auvelity, CREON, Cologuard Collection Kit, FIBRYGA, GEMTESA, Kyleena, LINZESS, Lynkuet, MYFEMBREE, Mirena, NEXPLANON, QULIPTA, Qelbree, SHINGRIX, SLYND, Veozah, ZURZUVAE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error